T. Rowe Price Associates
IKT icon

T. Rowe Price Associates’s Inhibikase Therapeutics IKT Stock Holding History

T. Rowe Price Associates’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86K Buy
50,874
+20,268
+66% +$36K ﹤0.01% 3024
2025
Q4 		$63K Hold
30,606
– – ﹤0.01% 3010
2025
Q3 		$50K Hold
30,606
– – ﹤0.01% 3014
2025
Q2 		$60K Buy
+30,606
New +$59.9K ﹤0.01% 2983

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates's IKT Position: Q1 2026 in Review

T. Rowe Price Associates increased its Inhibikase Therapeutics (IKT) stake by 66% in Q1 2026, buying an estimated $36K and bringing the position to 50,874 shares worth $86K. The position accounts for ﹤0.01% of the portfolio, ranked #3024.

T. Rowe Price Associates first reported a position in IKT in Q2 2025 and has held it in 4 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • T. Rowe Price Associates held 50,874 shares of Inhibikase Therapeutics worth $86K as of Q1 2026.
  • T. Rowe Price Associates bought 20,268 Inhibikase Therapeutics shares in Q1 2026, an estimated $36K.
  • Inhibikase Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3024 holding.
  • T. Rowe Price Associates first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.